2023-09-01 18:29:00 ET
More on Biogen
- Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
- Sanofi was mystery suitor in Reata Pharma bidding war - report
- Biogen And Alzheimer's Disease: Too Early To Celebrate
- Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
- RBC Capital sees Biogen stock undervaluing Leqembi prospects
- Biogen's Leqembi set for strong uptake based on Baird physician survey
- Seeking Alpha’s Quant Rating on Biogen
- Earnings data for Biogen
- Dividend for Biogen
For further details see:
Biogen in $1.5B unsecured loan facility for Reata acquisition